Terray raised $120 million to advance AI-driven drug discovery
Longevity Technology - 21-Oct-2024Their partnership with Calico focuses on age-related disease treatments
Join the club for FREE to access the whole archive and other member benefits.
CEO at Terray Therapeutics
Jacob is a distinguished inventor at the intersection of nanotechnology and synthetic chemistry. Prior to joining Terray full-time, he ran an NIH-funded lab at City of Hope, where he was an associate professor. He has more than 40 publications, 20 patents and over 11 thousand citations associated with his work. He was named one of the “Rising Stars and Young Nanoarchitects in Materials Science” by the Royal Society of Chemistry and was nominated for the Kabiller Young Investigator Award in Nanoscience and Nanomedicine.
Jacob received his PhD in organometallic chemistry from CalTech where he studied with Nobel Laureate Bob Grubbs. Jacob completed his postdoctoral training at MIT and Rice University focusing on synthetic chemistry and nanotechnology, and received a BA in chemistry from Harvard University (magna cum laude).
Visit website: https://terraytx.com/#team
See also: Terray Therapeutics - Biotechnology company accelerating AI-driven drug discovery
Details last updated 16-Oct-2022
Their partnership with Calico focuses on age-related disease treatments
Terray’s novel microarray technology, combines wet lab and computer-driven drug development